Search
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsDroxidopa
go.drugbank.com/drugs/DB06262ApprovedInvestigationalThere is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. … Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011.
Malacidin B
go.drugbank.com/drugs/DB14052ExperimentalMalacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312].
Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalIt is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181].
Malacidin A
go.drugbank.com/drugs/DB14051ExperimentalMalacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria [A33312]. … While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin A appears to act via its own distinct mechanism.
Synonyms: Malacidin ATenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil. … Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil].
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigational[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies … Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesOlaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalOlaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. … Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity